Intracellular delivery of the p38 mitogen-activated protein kinase Inhibitor SB202190 [4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] in renal tubular Cells: a novel strategy to treat renal fibrosis
Files
Publication date
2006
Authors
Prakash, J.
Sandovici, M.
Saluja, V.
Lacombe, M.
Schaapveld, R.Q.J.
de Borst, M.H.
van Goor, H.
Henning, R.H.
Proost, J.H.
Moolenaar, F.
Editors
Advisors
Supervisors
DOI
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
Keywords
Medical technology, Farmacie(FARM), Biomedische technologie en medicijnen, Pharmacology
Citation
Prakash, J, Sandovici, M, Saluja, V, Lacombe, M, Schaapveld, R Q J, de Borst, M H, van Goor, H, Henning, R H, Proost, J H, Moolenaar, F, Keri, G, Meijer, D F K, Poelstra, K & Kok, R J 2006, 'Intracellular delivery of the p38 mitogen-activated protein kinase Inhibitor SB202190 [4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] in renal tubular Cells: a novel strategy to treat renal fibrosis', Journal of Pharmacology and Experimental Therapeutics, vol. 319, pp. 1-12.